To Investigate the Cumulative Live Birth Rates Using GnRH Antagonist or Agonist Protocol for COS in ART Treatment (CLBR)
Sterility
About this trial
This is an interventional treatment trial for Sterility focused on measuring assisted reproductive technology, live birth, fertilization
Eligibility Criteria
Inclusion Criteria:
- Infertile women planning to undergo IVF/ICSI cycle using conventional GnRH agonist long protocol or GnRH antagonist protocol
- Age ≤ 38 years old
- Basal AFC 8~20
- Basal FSH≤10 IU/L
- Basal E 2 <200pmol/L
- Normal uterus and at least one side of the normal ovary
- Informed consent form signed
- Willing to follow the study protocol, and able to complete this study
Exclusion Criteria:
- Previous IVF/ICSI cycles >2
- Severe hydro-salpinx (Ultrasound shows hydro salpinx﹥2cm)
- Severe endometriosis (Grade III - IV)
- Polycystic ovarian syndrome (PCOS)
- History of recurrent miscarriages (>2 times of miscarriages)
- Plan to undergo ovarian stimulation for preimplantation genetic diagnosis or preimplantation genetic screening, oocyte donation, and social or medical freezing of oocytes
- Any major systemic disease that as per Investigator's discretion precludes subject for participation in the study
- With pregnancy contraindications
- Alcoholism, drug abuse, drug addiction or patients with uncured sexually transmitted disease
- According to the judgment of the Investigator, any medical condition or any concomitant surgery/medications that would interfere with evaluation of study medications
- Simultaneous participation in another clinical study
- Plan to use urinary gonadotrophin during COS treatment
Sites / Locations
- Peking University Third HospitalRecruiting
- The second hospital of Hebei Medical UniversityRecruiting
- The third hospital of Zhengzhoui Medical UniversityRecruiting
- Jiangsu Provincial HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
GnRH-ant protocol
GnRH-a long protocol
Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about 14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.